Show simple item record

dc.contributor.authorJohnston, Sen
dc.contributor.authorKilburn, Len
dc.contributor.authorEllis, Pen
dc.contributor.authorDodwell, Den
dc.contributor.authorCameron, Den
dc.contributor.authorHayward, Len
dc.contributor.authorIm, Y-Hen
dc.contributor.authorBraybrooke, Jen
dc.contributor.authorBrunt, Aen
dc.contributor.authorCheung, K-Len
dc.contributor.authorJyothirmayi, Ren
dc.contributor.authorRobinson, Aen
dc.contributor.authorWardley, Andrew Men
dc.contributor.authorWheatley, Den
dc.contributor.authorHowell, Anthonyen
dc.contributor.authorCoombes, Gen
dc.contributor.authorSergenson, Nen
dc.contributor.authorSin, H-Jen
dc.contributor.authorFolkerd, Een
dc.contributor.authorDowsett, Men
dc.contributor.authorBliss, Jen
dc.date.accessioned2013-10-29T12:06:01Z
dc.date.available2013-10-29T12:06:01Z
dc.date.issued2013-09
dc.identifier.citationFulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial. 2013, 14 (10):989-98 Lancet Oncolen
dc.identifier.issn1474-5488
dc.identifier.pmid23902874
dc.identifier.doi10.1016/S1470-2045(13)70322-X
dc.identifier.urihttp://hdl.handle.net/10541/304722
dc.description.abstractThe optimum endocrine treatment for postmenopausal women with advanced hormone-receptor-positive breast cancer that has progressed on non-steroidal aromatase inhibitors (NSAIs) is unclear. The aim of the SoFEA trial was to assess a maximum double endocrine targeting approach with the steroidal anti-oestrogen fulvestrant in combination with continued oestrogen deprivation.
dc.language.isoenen
dc.rightsArchived with thanks to The lancet oncologyen
dc.titleFulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial.en
dc.typeArticleen
dc.contributor.departmentRoyal Marsden NHS Foundation Trust, London, UK. stephen.johnston@rmh.nhs.uken
dc.identifier.journalLancet Oncologyen
html.description.abstractThe optimum endocrine treatment for postmenopausal women with advanced hormone-receptor-positive breast cancer that has progressed on non-steroidal aromatase inhibitors (NSAIs) is unclear. The aim of the SoFEA trial was to assess a maximum double endocrine targeting approach with the steroidal anti-oestrogen fulvestrant in combination with continued oestrogen deprivation.


Files in this item

This item appears in the following Collection(s)

Show simple item record